```html

Zoster Ophthalmicus – Visual Changes

What is Zoster ophthalmicus – visual changes?

Zoster ophthalmicus (ZO) is the involvement of the ophthalmic branch (V<sub>1</sub>) of the trigeminal nerve by the varicella‑zoster virus (VZV) that caused chicken‑pox earlier in life. When the virus reactivates, it travels along the V<sub>1</sub> pathway to the eye and surrounding structures. The most alarming feature is a sudden‑onset change in vision, which may range from mild blurring to severe loss of sight.

In simple terms, visual changes due to Zoster ophthalmicus refer to any new problem with eyesight that occurs alongside the classic shingles rash on the forehead, upper eyelid, or nose. Because the eye’s delicate tissues (cornea, conjunctiva, iris, retina, and optic nerve) can be directly infected, prompt recognition and treatment are essential to prevent permanent damage.

According to the CDC and Mayo Clinic, up to 50 % of patients with ZO develop eye complications, and visual loss occurs in roughly 10–15 % if therapy is delayed.

Common Causes

While the direct cause of Zoster ophthalmicus is reactivation of VZV, several factors increase the likelihood of visual changes once the virus involves the eye. The following conditions are commonly associated:

• Age ≥ 60 years – immune surveillance declines with age.
• Immunosuppression (HIV/AIDS, chemotherapy, organ transplantation, high‑dose steroids).
• Recent or prior shingles outbreak on the face or scalp.
• Diabetes Mellitus – impairs vascular supply to ocular tissues.
• Autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus) treated with biologics.
• Chronic ocular surface disease (dry eye, Stevens‑Johnson syndrome) that compromises corneal integrity.
• History of ocular trauma or surgery – creates a portal for viral spread.
• Systemic viral infections that transiently lower immunity (influenza, COVID‑19).
• Stress or severe emotional/physical strain – known trigger for VZV reactivation.
• Vaccination status – lack of shingles vaccine (Shingrix) increases risk.

Associated Symptoms

Visual disturbances rarely occur in isolation. Patients with Zoster ophthalmicus often experience a constellation of signs that help clinicians differentiate it from other eye conditions:

• Dermatomal rash – vesicular lesions on the forehead, scalp, or tip of the nose (Hutchinson’s sign).
• Eye pain – burning, stabbing, or deep orbital ache that may precede the rash.
• Photophobia – heightened sensitivity to light.
• Dryness or watery discharge from the affected eye.
• Redness (conjunctival injection) – often unilateral.
• Corneal ulcer or keratitis – painful epithelial defects.
• Iritis or anterior uveitis – pain and blurred vision with a hazy pupil.
• Retinal necrosis – may cause floaters, flashes, or peripheral vision loss.
• Ptosis or facial weakness – when the virus spreads to nearby cranial nerves.
• Fever, malaise, or lymphadenopathy – systemic signs of viral reactivation.

When to See a Doctor

Because vision can deteriorate rapidly, early medical evaluation is critical. Seek care promptly if you notice any of the following:

• New or worsening visual blur, double vision, or loss of part of the visual field.
• Severe eye pain that does not improve with over‑the‑counter analgesics.
• A vesicular rash on the forehead, scalp, or especially the side of the nose (Hutchinson’s sign).
• Redness and swelling of the eye accompanied by light sensitivity.
• Sudden onset of eye discharge that is thick, yellow, or green.

If you fall into any high‑risk category (elderly, immunocompromised, diabetic) even mild symptoms merit urgent evaluation.

Diagnosis

Diagnosing Zoster ophthalmicus with visual changes requires a combination of clinical assessment and targeted investigations.

Clinical Examination

• History – timeline of rash, pain, and visual symptoms; vaccination status; immune history.
• Visual acuity testing – Snellen chart or pinhole testing to quantify loss.
• Slit‑lamp examination – evaluates cornea, conjunctiva, anterior chamber for keratitis, ulceration, or uveitis.
• Fundoscopic (ophthalmoscopic) exam – looks for retinal lesions, vasculitis, or optic nerve edema.
• Hutchinson’s sign assessment – presence of lesions on the tip or side of the nose predicts ocular involvement.

Laboratory & Imaging Studies

• Polymerase chain reaction (PCR) of tear or lesion fluid – highly sensitive for VZV DNA.
• Viral culture – less common, reserved for atypical cases.
• Serology – not routinely needed; may show VZV IgG indicating prior infection.
• Anterior segment optical coherence tomography (AS‑OCT) – assesses corneal thickness and ulcer depth.
• Fundus photography or fluorescein angiography – detects retinal vasculitis or necrosis.

Treatment Options

The goals of therapy are to stop viral replication, control inflammation, prevent ocular complications, and preserve vision.

Antiviral Medications

• Acyclovir 800 mg orally five times daily for 7‑10 days.<sup>1</sup>
• Valacyclovir 1 g orally three times daily (preferred for better compliance).
• Famciclovir 500 mg orally three times daily.
• Intravenous acyclovir (10 mg/kg every 8 h) is reserved for severe ocular involvement, immunocompromised patients, or when oral therapy is contraindicated.

Corticosteroids

• Topical prednisolone acetate 1 % drops (q.i.d.–q.i.d.s.) to reduce anterior chamber inflammation, **after** antiviral therapy is started.
• Oral prednisone (0.5 mg/kg) may be added for severe uveitis or optic neuritis, tapering over 2‑4 weeks.
• Long‑term steroid use requires monitoring of intra‑ocular pressure.

Adjunctive Eye Care

• Lubricating eye drops (preservative‑free artificial tears) for corneal protection.
• Topical antiviral ointment (trifluridine 1 %) for epithelial keratitis, applied 5‑6 times daily.
• Cycloplegic agents (e.g., homatropine) to relieve painful ciliary spasm.
• Bandage contact lenses for persistent corneal erosions, placed by an ophthalmologist.

Home & Supportive Measures

• Cool compresses on the forehead to ease pain.
• Analgesics such as acetaminophen or ibuprofen (if no contraindication).
• Avoid rubbing the eye; keep hands clean to reduce secondary bacterial infection.
• Stay hydrated and maintain good nutrition to support immune recovery.

Follow‑Up Care

Patients should be re‑examined within 48‑72 hours of starting therapy, then weekly until the rash resolves and visual acuity stabilizes. Chronic complications (e.g., post‑herpetic neuralgia, glaucoma) require long‑term monitoring.

Prevention Tips

Because Zoster ophthalmicus arises from reactivation of a dormant virus, primary and secondary prevention strategies focus on boosting immunity and avoiding triggers.

• Shingles vaccination – Shingrix (recombinant zoster vaccine) is >90 % effective and is recommended for adults ≥50 years, especially those with chronic illnesses.
• Maintain a healthy immune system – balanced diet, regular exercise, adequate sleep (7‑9 h), and stress‑reduction techniques.
• Control chronic diseases – keep diabetes, hypertension, and HIV well‑managed.
• Avoid tobacco and excess alcohol – both impair immune response.
• Prompt treatment of facial shingles – initiating antivirals within 72 hours reduces the risk of ocular spread.
• Good hand hygiene – reduces secondary bacterial infection of lesions.
• Protect eyes during acute rash – wear sunglasses to limit photophobia.

Emergency Warning Signs

---

**References**

1. American Academy of Ophthalmology. Herpes Zoster Ophthalmicus. 2023. https://www.aao.org/eye-health/diseases/herpes-zoster-ophthalmicus
2. Centers for Disease Control and Prevention. Shingles (Herpes Zoster) and Eye Complications. 2022. https://www.cdc.gov/shingles/about/zo.html
3. Mayo Clinic. Shingles (Herpes Zoster) Treatment. 2024. https://www.mayoclinic.org/diseases-conditions/shingles/diagnosis-treatment/drc-20353016
4. National Institutes of Health. Herpes Zoster Ophthalmicus: Clinical Guidelines. 2023. PMCID
5. World Health Organization. Shingles vaccine (recombinant zoster vaccine) position paper. 2022.

```